1. Scrip
  2. >>R&D
  3. >>Trial Results

AstraZeneca's PACIFIC Update Bolsters Imfinzi's Lead In Stage III Lung Cancer

 
• By Emily Hayes
  
Generate a summary of this article
Listen to this article
Beta

Full PACIFIC data show strong overall survival benefit in all comers, though not in a post hoc analysis of those with low PD-L1 expression, about 20% of the population.

Investment maturity success as a business concept for growing wealth as a small tree gradually turning into a mature flying arrow plant as a financial metaphor for a successful investing on white.

Updated data from AstraZeneca PLC's pivotal PACIFIC study show a 32% overall survival benefit for Imfinzi in Stage III non-small cell lung cancer, a space where the PD-L1 inhibitor is already popular and the company has a monopoly. However, the trial results raise questions about whether a large subset of patients with low or no PD-L1 expression should be treated.

The Phase III PACIFIC study tested the immune checkpoint inhibitor Imfinzi (durvalumab) vs. placebo, randomized 2:1, after chemoradiation (CRT) therapy...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D